Cheng Y, Wang Q, Li K, Shi J, et al. Anlotinib vs placebo as third- or further-line treatment for patients with small cell lung cancer: a randomised, double-blind, placebo-controlled Phase 2 study. Br J Cancer 2021 May 18. pii: 10.1038/s41416-021-01356.
PMID: 34006926